Showing 3141-3150 of 5773 results for "".
- BlueRock Therapeutics and Foundation Fighting Blindness Partner for IRD Studyhttps://modernod.com/news/bluerock-therapeutics-and-foundation-fighting-blindness-partner-for-ird-study/2482178/BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer, and Foundation Fighting Blindness announced a collaboration to add a new cohort to the Foundation’s 'Uni-Rare natural history study' of people living with inherited retinal diseases (I
- Lenz Therapeutics Completes Merger with Graphite Bio; Debuts on Nasdaqhttps://modernod.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/Lenz Therapeutics announced the completion of its previously announced merger with Graphite Bio. The new combined company will operate under the name Lenz Therapeutics and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. &ldquo
- Study Compares Nanodropper Adaptor Versus Conventional Eye Drops for Glaucomahttps://modernod.com/news/study-compares-nanodropper-adaptor-versus-conventional-eye-drops-for-glaucoma/2482176/Nanodropper announced the publication of a company-sponsored study<
- Staar Surgical Celebrates Three Million Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-celebrates-three-million-implantable-collamer-lenses/2482170/Staar Surgical announced that more than 3 million Implantable Collamer Lens (ICLs) have been sold globally.[1] “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction
- Pandorum Technologies Secures $11 Million Investment to Advance its Regenerative Therapy for Corneal Blindness to Clinical Phasehttps://modernod.com/news/pandorum-technologies-secures-11-million-investment-to-advance-its-regenerative-therapy-for-corneal-blindness-to-clinical-phase/2482168/Pandorum Technologies announced the closure of a pre-Series B funding round, securing $11 million in investment to progress toward the first-in-human study of its flagship product, Kuragenx ("Liquid Cornea") to treat corneal blindness. The funding will also allow the
- NewSight Reality Unveils Transparent Optical Module (TOM) 2.0 at Vision Expo East 2024https://modernod.com/news/newsight-reality-unveils-transparent-optical-module-tom-20-at-vision-expo-east-2024/2482167/NewSight Reality (NSR), a provider of Augmented Reality (AR) technologies, announced the next generation of its Transparent Optical Module (TOM) 2.0 at the Vision Expo East meeting. Highlights of the new technology include a patented stray light shielding solution, active micro-len
- Virtual Vision Health Unveils New Features for Virtual Eye Prohttps://modernod.com/news/virtual-vision-health-unveils-new-features-for-virtual-eye-pro/2482166/Virtual Vision Health has announced it will showcase new testing features on its Virtual Eye Pro at Vision Expo East and ASCRS 2024. Developed and validated at Bascom Palmer Eye Institute, the virtual reality visual field headset is designed to increase practice efficienc
- Neurolens Restructures Leadership Teamhttps://modernod.com/news/neurolens-restructures-leadership-team/2482165/Neurolens announced a strategic leadership restructure, which includes Davis Corley, co-founder, returning as CEO. Other leadership hires: Gregory Boisse, SVP of Operations Nathan Schomas, SVP of Digital Innovation
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef
- Richard Lindstrom, MD, to Lead Eye Care Biopharmaceutical Company Surface Ophthalmicshttps://modernod.com/news/richard-lindstrom-md-to-lead-new-eye-care-biopharmaceutical-company-surface-ophthalmics/2482161/Surface Ophthalmics announced the appointment of Richard Lindstrom, MD, as Founder and Chairman. Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, PA. Dr. Lindstrom will lead in partnership with Surface’s Board of Directors, including